AI Biotech & Drug Discovery
IL

Isomorphic Labs

AI-first drug discovery heading to the clinic

VerifiedResearch confidence: MediumAI drug-discovery company
AlphaFold lineage$5B raisedToward clinic
Launched: November 17, 2026 ($5B Series C)Last verified: November 20, 2026

At a glance

Category
AI Biotech & Drug Discovery
Product type
AI drug-discovery company
Status
Private (research company)
Launch
November 17, 2026 ($5B Series C)
Pricing
Not applicable — research company, not a self-serve product.

Overview

Isomorphic Labs (spun out of Google DeepMind) closed an oversubscribed $5 billion Series C on November 17, 2026 to advance its AI drug-design engine and take candidates toward clinical trials.

Why it matters

A $5B Series C (Nov 17) to move AI-designed drugs toward clinical trials is the edition's defining biotech-AI event — though funding is a signal, not proof of clinical success.

Problem it solves

Drug discovery is slow and costly; AI methods aim to accelerate target and molecule design toward the clinic.

How it works

Isomorphic develops and applies AI models for biology and chemistry, partnering with pharma and advancing an internal pipeline.

Key capabilities

  • AI drug-design engine
  • Protein-structure-informed methods
  • Pharma partnerships
  • $5B Series C (Nov 17)

Integrations

Not publicly disclosed

Pricing & plans

Not applicable — research company, not a self-serve product.

View official pricing ↗

Use cases

  • Early-stage drug discovery
  • Target & molecule design
  • Pipeline development

Who should use it

  • • Pharma partners and researchers
  • • Investors tracking AI-bio

May not suit

  • • Developers seeking a usable API or product today

Independent editorial analysis

Strengths & limitations

Strengths

  • +Builds on DeepMind's protein-structure breakthroughs
  • +Exceptional capital runway after $5B raise
  • +Pharma partnerships and an internal pipeline

Limitations

  • –Not a self-serve product — no public access
  • –Funding does not guarantee clinical or regulatory success

Editorial assessment by aitoolslist.ai, distinct from vendor claims.

Alternatives & comparison

OptionPositioningWhen to prefer
Isomorphic LabsAI-first drug discovery heading to the clinicFeatured pick this edition
RecursionAI-driven drug discovery (public)For a public company with a clinical pipeline.
Insilico MedicineGenerative chemistryFor end-to-end generative drug design.
IambicAI drug discoveryFor physics-informed ML drug design.

Comparison reflects positioning; pricing and spec parity are not independently verified across all options.

Edition intelligence · AI Biotech & Drug Discovery

Why it was selected this edition

The edition's defining biotech-AI story (Nov 17). Note: funding is a supporting signal, not proof of product/clinical success — flagged for editorial verification.

Category rank: #1 this editionResearch confidence: MediumLaunch relevance: November 17, 2026 ($5B Series C)

Claim-level transparency

Research & verification

Our verification scope is explicit. A checked website does not mean the whole product has been independently audited.

Official websiteConfirmedhttps://www.isomorphiclabs.com
Launch / announcementConfirmed
Product capabilitiesCross-checkedFrom cited sources
PricingUnverifiedSee official pricing page
Performance benchmarksUnavailable